Ibuprofen and hydrogel-released ibuprofen in the reduction of inflammation-induced migration in melanoma cells

British Journal of Dermatology

Volumn 161, Issue 1, 2009, Pages 25-33

  Redpath, M ^a   Marques, C M G ^a   Dibden, C ^a   Waddon, A ^a   Lalla, R ^a   MacNeil, S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Ibuprofen; Inflammation; Melanoma migration; Nonsteroidal anti inflammatory drugs; Tumour necrosis factor

Indexed keywords

IBUPROFEN; POLOXAMER; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL ASSAY; CELL MIGRATION; CELL STIMULATION; CELL TYPE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HYDROGEL; INFLAMMATION; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL MOVEMENT; DELAYED-ACTION PREPARATIONS; HUMANS; HYDROGEL; IBUPROFEN; INFLAMMATION; MELANOMA; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67649973868     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09220.x     Document Type: Article

References (39)

1. Chan AT, Giovannucci EL, Meyerhardt JA et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005 294 : 914 23.
2. Jacobs EJ, Thun MJ, Bain EB et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007 99 : 608 15.
3. Cruz-Correa M, Shoskes DA, Sanchez P et al. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2006 4 : 1035 8.
4. Borthwick GM, Johnson AS, Partington M et al. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J 2006 20 : 2009 16.
5. Haycock JW, Wagner M, Morandini R et al. α-Melanocyte stimulating hormone inhibits NF-κB activation in human melanocytes and melanoma cell. J Invest Dermatol 1999 113 : 560 6.
6. Morandini R, Boeynaems JM, Hedley SJ et al. Modulation of ICAM-1 expression by alpha-MSH in human melanoma cells and melanocytes. J Cell Physiol 1998 175 : 276 82.
7. Haycock JW, Rowe SJ, Cartledge S et al. α-Melanocyte stimulating hormone reduces impact of proinflammatory cytokine and peroxide generated oxidative stress on keratinocyte and melanoma cell lines. J Biol Chem 2000 275 : 15629 36.
8. Zhu N, Eves PC, Katerinaki E et al. Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. J Invest Dermatol 2002 119 : 1165 71.
9. Eves P, Haycock J, Layton C et al. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer 2003 89 : 2004 15.
10. Cantón I, Eves PC, Szabo M et al. Tumor necrosis factor α increases and α-melanocyte-stimulating hormone reduces uveal melanoma invasion through fibronectin. J Invest Dermatol 2003 121 : 557 63.
11. Katerinaki E, Haycock JW, Lalla R et al. Sodium salicylate inhibits TNF-alpha-induced NF-kappaB activation, cell migration, invasion and ICAM-1 expression in human melanoma cells. Melanoma Res 2006 16 : 11 22. (Pubitemid 44133046)
12. Katerinaki E, Evans GS, Lorigan PC, MacNeil S. TNF-α increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer 2003 89 : 1123 9.
13. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007 7 : 429 42.
14. Steinberg GR. Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance. Cell Cycle 2007 6 : 888 94.
15. Ince MN, Elliott DE. Immunologic and molecular mechanisms in inflammatory bowel disease. Surg Clin North Am 2007 87 : 681 96.
16. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006 25 : 409 16.
17. Suganuma M, Okabe S, Marino MW et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999 59 : 4516 18.
18. Wang N, Thuraisingam T, Fallavollita L et al. The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res 2006 66 : 3062 70.
19. Miles DW, Happerfield LC, Naylor MS et al. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994 56 : 777 82.
20. Tsingotjidou AS, Zotalis G, Jackson KR et al. Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res 2001 21 : 971 8.
21. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology 2002 16 : 217 26.
22. Piva R, Belardo G, Santoro MG. NF-kappaB: a stress-regulated switch for cell survival. Antioxid Redox Signal 2006 8 : 478 86.
23. Okamoto T, Sanda T, Asamitsu K. NF-kappa B signaling and carcinogenesis. Curr Pharm Des 2007 13 : 447 62.
24. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001 357 : 539 45.
25. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005 7 : 211 17.
26. Ghanem GE, Comunale G, Libert A et al. Evidence for alpha-melanocyte- stimulating hormone (alpha-MSH) receptors on human malignant melanoma cells. Int J Cancer 1988 41 : 248 55.
27. Wu Q, Kirschmeier P, Hockenberry T et al. Transcriptional regulation during p21WAF1/CIP1-induced apoptosis in human ovarian cancer cells. J Biol Chem 2002 277 : 36329 37.
28. Cha D, O'Brien P, O'Toole EA et al. Enhanced modulation of keratinocyte motility by transforming growth factor-alpha (TGF-alpha) relative to epidermal growth factor (EGF). J Invest Dermatol 1996 106 : 590 7.
29. Bogden AE, Moreau J-P, Eden PA. Proliferative response of human and animal tumours to surgical wounding of normal tissues: onset, duration and inhibition. Br J Cancer 1997 75 : 1021 7.
30. Hofer SOP, Shrayer D, Reichner JS et al. Wound-induced tumour progression. A probable role in recurrence after tumor resection. Arch Surg 1998 133 : 383 9.
31. Eves P, Layton C, Hedley S et al. Characterization of an in vitro model of human melanoma invasion based on reconstructed human skin. Br J Dermatol 2000 142 : 210 22.
32. Eves P, Katerinaki E, Simpson C et al. Melanoma invasion in reconstructed human skin is influenced by skin cells - investigation of the role of proteolytic enzymes. Clin Exp Metastasis 2003 20 : 685 700. (Pubitemid 38019271)
33. Sibbald RG, Coutts P, Fierheller M, Woo K. A pilot (real-life) randomised clinical evaluation of a pain-relieving foam dressing (ibuprofen-foam versus local best practice). Int Wound J 2007 4 (Suppl. 1 16 23. (Pubitemid 46535989)
34. Price P, Fogh K, Glynn C et al. Why combine a foam dressing with ibuprofen for wound pain and moist wound healing? Int Wound J 2007 4 (Suppl. 1 1 3. (Pubitemid 46535990)
35. Reichle A, Bross K, Vogt T et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004 101 : 2247 56.
36. Spieth K, Kaufmann R, Gille J. Metronic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003 52 : 377 82.
37. Lejeune FJ, Monnier Y, Rüegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res 2006 16 : 263 5.
38. Benamouzig R, Uzzan B, Little J, Chaussade S. Low dose aspirin, COX-inhibition and chemoprevention of colorectal cancer. Curr Top Med Chem 2005 5 : 493 503. (Pubitemid 40974821)
39. Janssen A, Schiffmann S, Birod K et al. p53 is important for the antiproliferative effect of ibuprofen in colon carcinoma cells. Biochem Biophys Res Commun 2008 365 : 698 703. (Pubitemid 350234846)